EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma

Michele Massimino, Elena Tirrò iD, Stefania Stella, Cristina Tomarchio iD, Sebastiano Di Bella iD, Silvia Rita Vitale iD, Chiara Conti iD, Marialuisa Puglisi, Rosa Maria Di Crescenzo, Silvia Varricchio, Francesco Merolla iD, Giuseppe Broggi iD und 9 weitere

Biomolecules · 2025

DOI: 10.3390/biom15010146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Michele Massimino und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery and Medical-Surgical Specialties, University of Catania, 95123 Catania, Italy. Hauptthemen laut MEDLINE: Melanoma, Uveal Neoplasms, High-Throughput Nucleotide Sequencing. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the European Union's NextGenerationEU initiative under the Italian Ministry of University and Research as part of the PNRR - M4C2-I1…, European Union’s NextGenerationEU initiative under the Italian Ministry of University and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite advances in uveal melanoma (UM) diagnosis and treatment, about 50% of patients develop distant metastases, thereby displaying poor overall survival. Molecular profiling has identified several genetic alterations that can stratify patients with UM into different risk categories. However, these genetic alterations are currently dispersed over multiple studies and several methodologies, emphasizing the need for a defined workflow that will allow standardized and reproducible molecular analyses.

Methods

Following the findings published by “The Cancer Genome Atlas–UM” (TCGA-UM) study, we developed an NGS-based gene panel (called the UMpanel) that classifies mutation sets in four categories: initiating alterations (CYSLTR2, GNA11, GNAQ and PLCB4), prognostic alterations (BAP1, EIF1AX, SF3B1 and SRSF2), emergent biomarkers (CDKN2A, CENPE, FOXO1, HIF1A, RPL5 and TP53) and chromosomal abnormalities (imbalances in chromosomes 1, 3 and 8).

Results

Employing commercial gene panels, reference mutated DNAs and Sanger sequencing, we performed a comparative analysis and found that our methodological approach successfully predicted survival with great specificity and sensitivity compared to the TCGA-UM cohort that was used as a validation group.

Conclusions

Our results demonstrate that a reproducible NGS-based workflow translates into a reliable tool for the clinical stratification of patients with UM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaUveal NeoplasmsHigh-Throughput Nucleotide SequencingHumansUveal MelanomaPrognosisMutationBiomarkers, TumorWorkflowMaleFemale

Stichwörter der Autor:innen

NGSTCGAmolecular profilinguveal melanoma

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of General Surgery and Medical-Surgical Specialties, University of Catania, 95123 Catania, Italy.
  • Center of Experimental Oncology and Hematology, A.O.U. Policlinico "G. Rodolico-S. Marco", 95123 Catania, Italy.
  • Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
  • Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, 90127 Palermo, Italy.
  • Department of Human Pathology "G. Barresi", University of Messina, 98125 Messina, Italy.
  • Pathology Unit, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy.

ORCID-Profile: Elena Tirrò, Cristina Tomarchio, Sebastiano Di Bella, Silvia Rita Vitale, Chiara Conti, Francesco Merolla, Giuseppe Broggi, Federica Martorana, Alice Turdo, Miriam Gaggianesi, Giorgio Stassi, Rosario Caltabiano

Förderung

  • This work was supported by the European Union's NextGenerationEU initiative under the Italian Ministry of University and Research as part of the PNRR - M4C2-I1…
  • European Union’s NextGenerationEU initiative under the Italian Ministry of University and Research

Zitieren

APA

Massimino, M., Tirrò, E., Stella, S., Tomarchio, C., Di Bella, S., Vitale, S. R., Conti, C., Puglisi, M., Di Crescenzo, R. M., Varricchio, S., Merolla, F., Broggi, G., Martorana, F., Turdo, A., Gaggianesi, M., Manzella, L., Russo, A., Stassi, G., Caltabiano, R., …, & Vigneri, P. (2025). An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma. Biomolecules. https://doi.org/10.3390/biom15010146

Vancouver

Massimino M, Tirrò E, Stella S, Tomarchio C, Di Bella S, Vitale SR, et al. An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma. Biomolecules. 2025. doi:10.3390/biom15010146

BibTeX
@article{Massimino2025,
  author = {Massimino, Michele and Tirrò, Elena and Stella, Stefania and Tomarchio, Cristina and Di Bella, Sebastiano and Vitale, Silvia Rita and Conti, Chiara and Puglisi, Marialuisa and Di Crescenzo, Rosa Maria and Varricchio, Silvia and Merolla, Francesco and Broggi, Giuseppe and Martorana, Federica and Turdo, Alice and Gaggianesi, Miriam and Manzella, Livia and Russo, Andrea and Stassi, Giorgio and Caltabiano, Rosario and Staibano, Stefania and Vigneri, Paolo},
  title = {An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15010146}
}
Kostenlos starten →